BRIANNA PERRY: Open Payments
NPI 1578214706 · NEW LONDON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,958 in 74 payments from 20 companies in 2025. Trend: 2023 $26 · 2024 $1,213 · 2025 $1,958
Food & beverage: $1,849Education: $110
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $476 |
| Janssen Biotech, Inc. | 11 | $386 |
| UCB, Inc. | 8 | $286 |
| Amgen Inc. | 6 | $114 |
| Galderma Laboratories, L.P. | 4 | $106 |
| Lilly USA, LLC | 5 | $101 |
| SANOFI-AVENTIS U.S. LLC | 1 | $100 |
| Incyte Corporation | 2 | $47 |
| Organon LLC | 2 | $47 |
| Verrica Pharmaceuticals Inc. | 2 | $47 |
Products named: TREMFYA, Bimzelx, SKYRIZI, RINVOQ, DUPIXENT, OTEZLA, NEMLUVIO, TALTZ.
Industry payments across CT — which companies pay providers there.
